| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 04/08/2024 |
3. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 14,754 | D | |
| Common Stock | 31,172 | I | See footnote(1) |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (right to buy) | (2) | 06/16/2030 | Common Stock | 19,699 | 1.12 | D | |
| Explanation of Responses: |
| 1. The shares are held by Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE. |
| 2. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. |
| Remarks: |
| Exhibit 24 - Power of Attorney |
| /s/ Ben Hohl, by power of attorney | 04/10/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
POWER OF ATTORNEY
The undersigned, as a Section 16 reporting person of Enliven Therapeutics. Inc. (the “Company”),
hereby constitutes and appoints Ben Hohl, Galya Blachman and Frank Silanos. and each of them. As
the undersigned’s true and lawful attorney-in-fact to:
1. complete and execute Forms 3. 4 and 5 and other forms and all amendments thereto as such
attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16 of
the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated
thereunder, or any successor laws and regulations, as a consequence of the undersigned’s ownership,
acquisition or disposition of securities of the Company; and
2. do all acts necessary in order to file such forms with the SEC, any securities exchange or national
association, the Company and such other person or agency as the attorneys-in-fact shall deem
appropriate.
The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or
cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact
in serving in such capacity at the request of the undersigned. are not assuming. nor is the Company
assuming. any of the undersigned’s responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934 (as amended).
This Power of Attorney shall remain in full force and effect until the undersigned is no longer
required to file Forms 3. 4 and 5 with respect to the undersigned’s holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the Company and the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of
this 4th day of April. 2024.
Signature: /s/ Lori Kunkel
Print Name: Lori Kunkel
-0-
Normal.dotm